

Medicines Patent Pool Governance Board Meeting #30

April 13, 2021
held virtually due to Covid-19

Attendees

Governance Board Members:

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Manica Balasegaram, Patrizia Carlevaro, Claudia Chamas, Jinliang Li, Peter Maybarduk, John-Arne Røttingen, and Jayashree Watal.

Non-voting members:

Peter Beyer – EAG Chair, Marion (Amy) Dietterich – WIPO Observer, Jan Akko Eleveld – Unitaid Project Team, Robert Matiru – Unitaid Executive Team, Luis Pizarro de Trenquallye – Unitaid Executive Team, and Karin Timmermans - Unitaid Strategy Team.

Medicines Patent Pool Foundation Management Team:

Charles Gore – Executive Director, Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation, Esteban Burrone – Head of Policy, Vincent Chauvin – CFO, Head of Human Resources, Gelise McCullough – Head of Communications, Sandra Nobre – Head of Business Development, Chan Park – General Counsel, Andrew Goldman - Associate Counsel, Nataliya Omelchuk - Associate Counsel, and Agnese Tonnina – Grants and Operations Manager.

Auditor:

Aurore De San Nicolas – Audit & Assurance Manager, Deloitte SA

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Approves and adopts the minutes of Governance Board meeting #29 held on 13th and 14th October 2020. The Board approves the updated agenda of the Governance Board Meeting #30.
2. “In response to the exceptional need for health technologies for the world to respond to Covid-19, the Board authorises the continuation of the temporary expansion of MPP’s remit to include any health technologies where licensing could improve access for LMICs. This Board resolution may be amended at any time but in any case will be reviewed **at the Board meeting following WHO’s announcement that COVID-19 no longer represents a PHEIC or is no longer a pandemic.**”

3. Approves the strategy development process presented [for the new 2023-25 organisational strategy] and requests the MPP Management to move forward with its implementation. An update should be presented to the Board at the Autumn 2021 Board meeting.
4. Approves the 2020 financial statements and the auditors' report. Further approves the proposed changes to the Financial Management Policy and the initiation of the process for changing bank in India.
5. Approves the risk assessment report.
6. Approves the definition of *Independent Board Member*, as follows:

“A majority of the Governance Board Members shall be independent. A Governance Board Member shall be considered “independent” if the Governance Board Member or immediate family member of that Governance Board Member currently and for the period of three years prior:

- (a) Is not employed by the Medicines Patent Pool; and
- (b) Is not employed or affiliated in a senior capacity by any donor to MPP;
- (c) Maintains no connection with the Medicines Patent Pool that would be perceived as a conflict of interest.

Assessment of the independence of the Governance Board Members shall be performed on an annual basis.”

7. Approves the revised Chart of Authorities [setting out the respective powers of approval of the Governance Board and the Executive Director].
8. Approves the renewal of Marie-Paule Kieny as Chair of the MPP Governance Board for a third 2-year term commencing on 01.09.2021.
9. Agrees that it is good governance to abide by the regulations outlined in MPP's Statutes and By-laws, which states that the initial 2-year term of a Board member may be renewed twice, to a maximum of six years. In that regard, the Board concludes that there are currently no exceptional circumstances that would justify the extension of Claudia Chamas and Jayashree Watal, who are completing their third term. However, recognising their significant experience and expertise in many matters that are crucial to MPP and considering that MPP is about to embark on the elaboration of a new three-year strategic plan, the Board wishes to invite them – as well as other former Board members, as appropriate – in a personal capacity to participate in the 2022 Strategy retreat. They could also be further consulted or invited to attend specific SPC meetings in which the new strategy will be discussed.